Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD

Timothy E Albertson; Willis S Bowman; Richart W Harper; Regina M Godbout; Susan Murin

doi:10.2147/COPD.S191845

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD

Int J Chron Obstruct Pulmon Dis. 2019 Jun 6:14:1251-1265. doi: 10.2147/COPD.S191845. eCollection 2019.

Authors

Timothy E Albertson^{1

2}, Willis S Bowman^{1

2}, Richart W Harper^{1

2}, Regina M Godbout^{2

3}, Susan Murin^{1

2}

Affiliations

¹ Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, UC Davis, Sacramento, CA, USA.
² Department of Veterans Affairs, Northern California Health Care System, Mather, CA, USA.
³ Department of Internal Medicine, Division of General Medicine, UC Davis, Sacramento, CA, USA.

Abstract

The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta₂-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.

Keywords: COPD; LABA; LAMA; fixed-dose combination inhalers; long-acting beta2-adrenergic agonists; long-acting muscarinic antagonists; umeclidinium bromide; vilanterol trifenatate.

Publication types

Review

MeSH terms

Administration, Inhalation
Adrenergic beta-2 Receptor Agonists / administration & dosage*
Adrenergic beta-2 Receptor Agonists / adverse effects
Adrenergic beta-2 Receptor Agonists / pharmacokinetics
Benzyl Alcohols / administration & dosage*
Benzyl Alcohols / adverse effects
Benzyl Alcohols / pharmacokinetics
Bronchodilator Agents / administration & dosage*
Bronchodilator Agents / adverse effects
Bronchodilator Agents / pharmacokinetics
Chlorobenzenes / administration & dosage*
Chlorobenzenes / adverse effects
Chlorobenzenes / pharmacokinetics
Drug Combinations
Dry Powder Inhalers
Evidence-Based Medicine
Humans
Lung / drug effects*
Lung / physiopathology
Muscarinic Antagonists / administration & dosage*
Muscarinic Antagonists / adverse effects
Muscarinic Antagonists / pharmacokinetics
Pulmonary Disease, Chronic Obstructive / diagnosis
Pulmonary Disease, Chronic Obstructive / drug therapy*
Pulmonary Disease, Chronic Obstructive / physiopathology
Quinuclidines / administration & dosage*
Quinuclidines / adverse effects
Quinuclidines / pharmacokinetics
Recovery of Function
Treatment Outcome

Substances

Adrenergic beta-2 Receptor Agonists
Benzyl Alcohols
Bronchodilator Agents
Chlorobenzenes
Drug Combinations
GSK573719
Muscarinic Antagonists
Quinuclidines
vilanterol